Abstract

VELEZ GOMEZ, Sara et al. Pharmacogenomic application of the CYP2C19, CYP2C9 and VKORC1 genes implicated in the metabolism of clopidogrel and warfarin. Rev. Colomb. Cardiol. [online]. 2018, vol.25, n.6, pp.396-404. ISSN 0120-5633.  https://doi.org/10.1016/j.rccar.2018.05.005.

The study of the variations in DNA and RNA sequencing as regards the response to different drugs has become a particularly promising area for their application in clinical genomics and personalised genome studies. Drugs of daily use in the treatment of cardiovascular diseases have shown variations in the response depending on the genetic variations of the individuals. Two drugs have gathered worldwide interest: warfarin, an oral anticoagulant, and clopidogrel, an antiplatelet drug, which act by altering different pathways that constitute the clotting cascade either by directly limiting the production of thrombin, or by blocking other activators of the pathway. The genetic changes that have been associated with the reduction in the enzyme activity of these drugs occur in the genes, CYP2C19 for clopidogrel, and the genes, CYP2C9 and VKORC1 for warfarin. The genetic variations identified for these genes are associated with genotype profiles that determine the dose required by the patient. It is from there, sciences like pharmacogenomics have as their aim to provide a more objective diagnostic aid in order to optimise time and resources, as well as to reduce the risk of the patient suffering complications that may compromise their life.

Keywords : Pharmacogenomics; Clopidogrel; Warfarin; Single nucleotide polymorphisms.

        · abstract in Spanish     · text in Spanish     · Spanish ( pdf )